ReviewPediatric nephrology (Berlin, Germany)2010
The evolving place of incretin-based therapies in type 2 diabetes.
Review in Pediatric nephrology (Berlin, Germany), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 42 citations in OpenAlex.
- Incretin-based therapy: a new horizon in diabetes management.Journal of diabetes and metabolic disorders · 2024Review
- A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Review
- Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Frontiers in pharmacology · 2018Review
- Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes.Journal of diabetes research · 2016Article
- The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles.Pharmaceutical research · 2015Article
- The effects of glucose-lowering therapies on diabetic kidney disease.Current diabetes reviews · 2015Review
- The regions within the N-terminus critical for human glucagon like peptide-1 receptor (hGLP-1R) cell surface expression.Scientific reports · 2014Article
- Clinical therapeutic strategies for early stage of diabetic kidney disease.World journal of diabetes · 2014Review
- Structure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors.Acta pharmacologica Sinica · 2012Review
- Recent advances in gut nutrient chemosensing.Current medicinal chemistry · 2012Review
- Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.Drugs · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment options for type 2 diabetes based on the action of the incretin hormone glucagon-like peptide-1 (GLP-1) were first introduced in 2005. These comprise the injectable GLP-1 receptor agonists solely acting on the GLP-1 receptor on the one hand and orally active dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) raising endogenous GLP-1 and other hormone levels by inhibiting the degrading enzyme DPP-4. In adult medicine, both treatment options are attractive and more commonly used because of their action and safety profile. The incretin-based therapies stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner and carry no intrinsic risk of hypoglycaemia. GLP-1 receptor agonists allow weight loss, whereas DPP-4 inhibitors are weight neutral. This review gives an overview of the mechanism of action and the substances and clinical data available.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.